Evertex Fabrinology Ltd. logo

Evertex Fabrinology Ltd. (1470)

Market Closed
12 Dec, 05:30
TWSE TWSE
NT$
23. 10
+0.35
+1.54%
NT$
1.96B Market Cap
29.76 P/E Ratio
0% Div Yield
20,147 Volume
0 Eps
NT$ 22.75
Previous Close
Day Range
22.6 23.9
Year Range
19.55 27.6
Want to track 1470 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

1470 closed yesterday higher at NT$23.1, an increase of 1.54% from Thursday's close, completing a monthly increase of 1.09% or NT$0.25. Over the past 12 months, 1470 stock gained 0.22%.
1470 pays dividends to its shareholders, with the most recent payment made on Aug 15, 2025. The next estimated payment will be in In 8 months on Aug 15, 2026 for a total of NT$1.01.
The last earnings report, released on Jun 25, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.06%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on TWSE (TWD).

1470 Chart

Similar

Chitec Technology Co., Ltd.
NT$ 61
-4.54%
Chang Ho Fibre Corporation
NT$ 11.95
0%
Louisa Professional Coffee Ltd.
NT$ 92
+0.11%
Ta Yih Industrial Co., Ltd.
NT$ 24.05
-0.21%
Liwanli Innovation Co., Ltd.
NT$ 24.85
0%

Evertex Fabrinology Ltd. (1470) FAQ

What is the stock price today?

The current price is NT$23.10.

On which exchange is it traded?

Evertex Fabrinology Ltd. is listed on TWSE.

What is its stock symbol?

The ticker symbol is 1470.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 1.96B.

Has Evertex Fabrinology Ltd. ever had a stock split?

No, there has never been a stock split.

Evertex Fabrinology Ltd. Profile

Textiles, Apparel & Luxury Goods Industry
Consumer Discretionary Sector
Mr. Poliang Yeh CEO
TWSE Exchange
TW0001470003 ISIN
TW Country
- Employees
- Last Dividend
29 Jun 2000 Last Split
10 Dec 2009 IPO Date

Overview

Chunghwa Chemical Synthesis & Biotech Co., Ltd. is a leading company focused on the research, development, manufacture, and sales of active pharmaceutical ingredients (APIs) primarily in Taiwan and the United States. The company has a rich history since its establishment in 1964, originally known as China Chemical Synthesis Industry Co., Ltd. Headquartered in New Taipei City, Taiwan, it has made significant strides in the pharmaceutical industry by providing a wide range of API products and bulk pharmaceuticals. Additionally, Chunghwa Chemical Synthesis & Biotech offers comprehensive research and development, and contract manufacturing services, catering to the needs of new drug developers and generic drug companies alike.

Products and Services

  • API Products:

    Chunghwa Chemical Synthesis & Biotech specializes in an extensive range of API products. These include immunosuppressants for preventing organ transplant rejection, oncology drugs for cancer treatment, antivirals for viral infections, and immunomodulating agents that modify the immune system. Additionally, the company manufactures peptide drugs that represent a significant advancement in pharmaceuticals.

  • Bulk Pharmaceutical Products:

    The company's portfolio includes a versatile range of bulk pharmaceutical products. This encompasses anti-anxiety agents for anxiety disorders, antidiabetics for diabetes management, laxatives for treating constipation, antifungals for fungal infections, antihistamines for allergy relief, antiseptics for preventing infection, antiulcerants for ulcer treatment, and cardiovascular drugs for heart conditions. They also produce skeletal muscle relaxants for muscle spasms, hypolipemics for lowering lipid levels, antineoplastics for cancer treatment, antihyperlipidemias for cholesterol management, and immunosuppressants for immune system regulation.

  • Research and Development:

    The company invests heavily in research and development to innovate and improve pharmaceutical products. This commitment ensures that Chunghwa Chemical Synthesis & Biotech stays at the forefront of pharmaceutical advancements, offering cutting-edge solutions to the healthcare industry.

  • Contract Manufacturing Services:

    Chunghwa Chemical Synthesis & Biotech provides tailor-made contract manufacturing services, offering its expertise and facilities to both new drug developers and generic drug companies. These services extend from the initial phases of drug development through to full-scale production, reflecting the company's adaptability and capacity to meet a diverse range of client needs.

Contact Information

Address: 64 Ta?Cheng Street, Taipei, Taiwan, 103005
Phone: 886 0 3322 2241